ACMT Toxicology Visual Pearl – Lead it Be?

5. All of the above All patients with retained ballistic fragments are at risk for elevated blood lead levels (BLL) and clinical toxicity. The presence of multiple fragments, an associated fracture, or fragments within a bodily fluid compartment, such as a joint space, conveys a higher risk. Still, soft tissue fragments have also been reported to result in elevated BLL and clinical toxicity. Background In 2020, there were nearly 100,000 nonfatal firearm injuries in the US [1]. Retained ballistic fragments are common, occurring in 75% of patients with a nonfatal gunshot wound, with soft tissue being the most common location [2]. Most patients still have at least one retained fragment present at discharge, as soft tissue fragments are typically not removed due to concern for causing more harm with removal [2]. Can retained ballistic fragments cause lead toxicity? What would be their symptoms? There have been numerous case studies of clinical lead poisoning in patients with retained ballistic fragments [3-7]. Blood lead levels requiring immediate medical attention are 70 mcg/dL or higher in adults and 45 mcg/dL or higher in children [8,9]. CDC data from 2003-2012 show that retained ballistic fragments were associated with 4.9% of all BLL ≥ 80 mcg/dL [10]. Patients with elevated BLLs do not always present with clinical symptoms of lead poisoning. Symptoms include abdominal discomfort, nausea, vomiting, constipation, cognitive dysfunction, irritability, anxiety, depression, headache, fatigue, and joint pain. Lead poisoning can also lead to hypertension, renal dysfunction, anemia, increased susceptibility to infection, and both male and female infertility [11]. A 2019 meta-analysis showed that patients with retained ballistic fragments have significantly higher BLLs than the rest of the population, with median levels above the CDC surveillance threshold [12]. Which patients with retained ballistic fragments are at risk for elevated BLLs? [12,13] Ballistic fragments within a bodily fluid compartment, such as the joint, carry the highest risk for elevated BLLs and clinical toxicity. Multiple ballistic fragments and the presence of a bony fracture are higher risk for elevated BLLs. While soft tissue ballistic fragments were traditionally thought to be low risk, symptomatic lead toxicity has been reported with retained soft tissue fragments alone. When should blood lead levels be checked in patients with retained ballistic fragments? [12,13] Blood lead levels can peak at any time, depending on the location and the number of fragments involved. Symptoms of lead toxicity can present years from the index injury, with a median time to symptom onset of 9 years. While there are no universal testing guidelines, the two most recently published recommendations are as follows: The Journal of Trauma and Acute Care Surgeons in 2019 recommended blood lead levels be drawn every 3 months for the first year after injury, and to attempt removal of retained fragments in anyone with a BLL > 5 mcg/dL if no potential for worsening the injury [12]. A 2021 meta-analysis published in Clinical Toxicology recommended that BLLs be drawn at index presentation, every 3 months for the first year, and then annually following that, in addition to any time someone becomes symptomatic [13]. Clinicians should retain a high index of suspicion for lead toxicity in those with known retained ballistic fragments. Clinicians should also ask patients with elevated BLL of unknown origin about the possibility of retained metal fragments in the body. Should retained ballistic fragments be removed? [12,13] Current indications for ballistic fragment removal at index presentation include presence within a joint space, presence within a vascular lumen, or nerve impingement. Consideration may be given to the removal of intra-abdominal or intra-spinal ballistic fragments, weighing risk/benefit carefully. After index presentation, other indications for consideration of removal include persistent pain, infection, and fracture non-union. Patients with rising BLLs and/or symptoms of clinical toxicity should have the ballistic fragment removed whenever possible. Patients with symptomatic toxicity and elevated BLLs improve following ballistic fragment removal. Some patients may be candidates for lead chelation, in conjunction with ballistic fragment removal, in a multidisciplinary approach. Bedside Pearls